News

Filter

Current filters:

Biogen IdecPatents

Biogen prevails in EU exclusivity battle for MS drug Tecfidera

Biogen prevails in EU exclusivity battle for MS drug Tecfidera

25-11-2013

US biotech company Biogen Idec saw its shares leap 10% to an all-time high of nearly $278 on Friday,…

Biogen IdecBiotechnologyEuropeNeurologicalPatentsRegulationTecfidera

US Court denies re-hearing of Arzerra patent case

16-07-2013

Danish drugmaker Genmab (OMX: GEN) says that the US Court of Appeals for the Federal Circuit has declined…

ArzerraBiogen IdecBiotechnologyGenentechGenmabGlaxoSmithKlineLegalNorth AmericaOncologyPatentsPharmaceutical

Biogen Idec sees EU launch delay for Tecfidera on patent issues

31-05-2013

In a filing with the Securities and Exchange Commission, US biotech firm Biogen Idec (Nasdaq: BIIB) said…

Biogen IdecBiotechnologyEuropeMarkets & MarketingNeurologicalPatentsRegulationTecfidera

Briefs: Biogen Idec gets new Tecfidera patent; Fresenius Kabi to buy Indian facility

20-03-2013

US biotech firm Biogen Idec (Nasdaq: BIIB) yesterday announced that the US Patent and Trademark Office…

BG-12Biogen IdecBiotechnologyFresenius KabiMergers & AcquisitionsParenteral Drugs IndiaPatentsProductionTecfidera

US court rules in GlaxoSmithKline’s favor in Arzerra patent dispute

18-11-2011

A US District Court has entered final judgment in favor of UK pharma giant GlaxoSmithKline (LSE: GSK)…

ArzerraBiogen IdecBiotechnologyGenentechGenmabGlaxoSmithKlineLegalNorth AmericaOncologyPatentsPharmaceuticalRoche

Biotech - the battle of branded drugs and generics

28-06-2010

With a string of patent protections expiring in the USA in 2010 onwards, many large pharmaceutical and…

Biogen IdecBiotechnologyGenericsGilead SciencesHealthcareMarkets & MarketingNorth AmericaPatents

Genentech and Biogen sue GlaxoSmithKline and Genmab over Arzerra patent

26-03-2010

US biotechnology giant Genentech, a wholly-owned subsidiary of Switzerland’s Roche, and Biogen Idec…

ArzerraBiogen IdecBiotechnologyGenentechGenmabGlaxoSmithKlineOncologyPatentsPharmaceuticalRituxanRoche

COMPANY SPOTLIGHT

Menarini

Back to top